Active ingredientDeucravacitinibCat. No. P-D066-001CAS 1609392-27-9Family · Pharmaceutical analytical standards
Deucravacitinib
The first TYK2 kinase inhibitor, taken by mouth, approved in the United States in 2022 for moderate to severe plaque psoriasis: it dampens the signals of inflammatory cytokines such as IL-23 and IL-12. This family brings together the active ingredient, metabolites, labelled standards and other impurities.
Did you know?The prefix 'deu-' recalls deuterium, the heavy hydrogen present in the molecule; moreover, it does not block the enzyme's active site but latches onto its regulatory domain.
Go to the active ingredient →Active ingredientDeucravacitinibCat. No. P-D066-001CAS 1609392-27-9
MetaboliteDeucravacitinib BMT-334616 MetaboliteCat. No. P-D066-002
MetaboliteDeucravacitinib M-11 MetaboliteCat. No. P-D066-003
Isotopically labelledDeucravacitinib D3Cat. No. P-D066-005CAS 1609393-89-6
ImpurityDeucravacitinib Impurity 1Cat. No. P-D066-010CAS 1609394-10-6
Impurity2-Methoxy-3-nitrobenzamideCat. No. P-D066-011CAS 722538-98-9
ImpurityDeucravacitinib ImpurityCat. No. P-D066-012CAS 1609394-08-2
ImpurityDeucravacitinib Impurity 2Cat. No. P-D066-013CAS 2222717-56-6
ImpurityDeucravacitinib Impurity 3Cat. No. P-D066-014CAS 2245111-21-9
ImpurityDeucravacitinib Impurity 4Cat. No. P-D066-015CAS 1442437-21-9
ImpurityDeucravacitinib Impurity 5Cat. No. P-D066-016CAS 1609394-05-9
ImpurityDeucravacitinib Impurity 6Cat. No. P-D066-017CAS 1609393-48-7
ImpurityDeucravacitinib Impurity 7Cat. No. P-D066-018CAS 1609394-23-1
ImpurityDeucravacitinib Impurity 8Cat. No. P-D066-019CAS 2417138-48-6
ImpurityDeucravacitinib Impurity 9Cat. No. P-D066-021CAS 2245111-18-4
ImpurityN,N'-Dimethylformamide dimethyl acetalCat. No. P-D066-023CAS 4637-24-5No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.